IMC Chicago
SMMT icon

IMC Chicago’s Summit Therapeutics SMMT Stock Holding History

IMC Chicago’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.78M Buy
94,000
+10,300
+12% +$167K ﹤0.01% 2688
2025
Q4 		$1.46M Sell
83,700
-91,600
-52% -$1.72M ﹤0.01% 2672
2025
Q3 		$3.62M Sell
175,300
-151,300
-46% -$3.67M ﹤0.01% 1811
2025
Q2 		$6.95M Buy
+326,600
New +$7.45M ﹤0.01% 1204

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IMC Chicago's SMMT Position: Q1 2026 in Review

IMC Chicago sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 29,704 shares — an estimated $480K sold.

IMC Chicago first reported a position in SMMT in Q4 2025 and held it in 1 quarter. The position peaked at $520K in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • IMC Chicago reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • IMC Chicago sold 29,704 Summit Therapeutics shares in Q1 2026, an estimated $480K.
  • IMC Chicago first reported a position in Summit Therapeutics in Q4 2025 and held it in 1 quarter.
  • IMC Chicago's Summit Therapeutics position peaked at $520K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.